High-dose chemotherapy (HDC) with hematopoietic support appears promising in the treatment of breast cancer, although reinfusion of contaminating tumor cells may contribute to disease relapse. Ex vivo expansion may reduce tumor cell content through use of a small inoculum volume and by passive purging during culture. We assessed the ex vivo expansion potential of tumor cell positive bone marrow (BM) from breast cancer patients and the effect of ex vivo expansion on tumor cell content. Cryopreserved/thawed mononuclear cell (C/T MNC) BM harvests with known tumor cell contamination (n = 7) were assessed for tumor cells preand post-expansion using immunocytochemical (ICC) staining. Pre-expansion inoculum samples contained a range of 6-2128 tumor cells per 5.0 × 10 6 nucleated cells. Ex vivo expansion resulted in fold expansions of 6.67 and 11.37 for total cells and CFU-GM, respectively. Tumor cells were undetectable in four of the seven postexpansion samples and were reduced in the remaining three samples. The data demonstrate passive purging of breast cancer cells during ex vivo expansion, with hematopoietic progenitor cell expansion comparable to that of normal BM. Reduction in tumor cell number contained in the small volume culture inoculum combined with passive purging during the ex vivo expansion process suggest a potential 2-4+ log reduction in tumor cell content in the reinfused cell product.
Immunologic techniques have revealed tumor cell infiltration of the BM in as many as 48% of early stage breast cancer patients at the time of diagnosis. [1] [2] [3] [4] The presence of tumor cells in the BM has been shown to be predictive of relapse in early stage [5] [6] [7] and advanced stage 8, 9 breast cancer patients. In addition, the number of tumor cells identified in the BM has been correlated with shorter disease-free and overall survival. 6 Although the prognostic significance of tumor cells in PBPC collections requires further evaluation, Correspondence: Dr BI Lundell, Aastrom Biosciences, Inc., 24 Frank Lloyd Wright Drive, Domino's Farms, Lobby L, Ann Arbor, MI 48105, USA Received 21 January 1998; accepted 18 March 1998 a trend of higher relapse rates in breast cancer patients receiving tumor cell positive PBPC collections has been reported. 7 High-dose chemotherapy with hematopoietic rescue appears promising in the treatment of breast cancer, 10, 11 but the presence of contaminating tumor cells in the reinfused hematopoietic cell product remains a concern. Retrovirally mediated gene marking techniques and retrospective clinical trials have demonstrated in patients with acute myelogenous leukemia, neuroblastoma, B cell lymphoma, chronic lymphocytic leukemia, or chronic myelogenous leukemia that reinfusion of contaminating tumor cells present in the BM harvest can contribute to disease relapse in the BM itself or in extramedullary sites. [12] [13] [14] [15] [16] The contribution of reinfused tumor cells to the relapse of breast cancer is currently unclear. Studies monitoring the reinfusion of tumor positive hematopoietic cell products in breast cancer patients were unable to detect a correlation between tumor cell contamination and site of relapse. 6, 8 In vitro clonogenic assays suggest, however, that tumor cells remaining in BM harvests or PBPC collections can be viable and clonogenic 12, 13, 17, 18 potentially contributing to disease relapse. The homing of reinfused tumor cells to sites of previous disease may prevent the distinction between relapse due to residual tumor cells or reinfused tumor cells. Altered adhesion receptor expression or function, similar to that previously demonstrated in breast cancer tumor cells, 19 may contribute to the homing of reinfused tumor cells from the circulation to a microenvironment capable of supporting tumor cell growth. 20, 21 Many HDC trials are currently conducted without some form of tumor cell purging. Removal of tumor cells from the reinfused hematopoietic stem cell product may result in improved diseasefree and overall patient survival.
Previous ex vivo expansion studies using CD34 + PBPC derived from breast cancer patients have reported median progenitor expansions of 10-to 46-fold, 22 with a relative disadvantage of tumor cell growth compared to hematopoietic cell growth in cultures seeded with tumor cell lines. 23 The ex vivo expansion potential of primary tumor cells and their impact on hematopoietic progenitor cell expansion in a stromal-based culture system has not been evaluated. The intent of this study was (1) to evaluate the ex vivo expansion potential of BM samples obtained from stage IV breast cancer patients which were known to be tumor cell positive using a small scale culture system, and (2) to determine the effect of ex vivo expansion on tumor cell content.
Materials and methods

Bone marrow samples
The Duke University Bone Marrow Transplant Program has performed a series of clinical protocols for patients utilizing a variety of purging techniques. Seven back-up BM samples collected from stage IV breast cancer patients having a median age of 46 years (range 34-51 years) were available for ex vivo expansion. All seven patients exhibited tumor cell infiltration of the BM by routine histologic examination of BM biopsies. The BM samples used for these studies were obtained using standard BM harvesting techniques.
For a controlled comparison, small volume BM aspirates (n = 7) were collected after obtaining informed consent from normal volunteers having a median age of 37 years (range 21-45 years). Briefly, two aspirates were collected from adjacent sites on the posterior iliac crest. For each aspiration, 3 ml of BM was collected from each of four quadrants, rotating the BM needle bevel 90°between quadrants, for a total volume of 12 ml. Cells were anticoagulated with 20 U/ml preservative-free heparin (Apothecon, Princeton, NJ, USA) and processed within 5 h of collection.
Sample processing
An unpurged aliquot of patient BM MNC was control rate cryopreserved and stored for a median period of 33 months (range 12-42 months). Cryopreserved patient samples were shipped on dry ice to Aastrom Biosciences, where they were stored in the vapor phase of liquid nitrogen for up to 1 month prior to thawing for initial tumor cell content assessment and ex vivo expansion. Cryopreserved samples were thawed rapidly in a 37°C circulating waterbath, diluted with approximately two volumes of long-term bone marrow culture medium ( (LTBMC; Iscove's modified Dulbecco's medium (IMDM) with 4 mm l-glutamine (Gibco BRL, Grand Island, NY, USA), 10% fetal bovine serum (FBS; BioWhittaker, Walkersville, MD, USA), 10% horse serum (Gibco BRL), 20 g/ml vancomycin (Vancocin HCl, Lilly, Indianapolis, IN, USA), 5 g/ml gentamicin (Fujisawa USA, Deerfield, IL, USA), and 5 m hydrocortisone (Solu-Cortef, Upjohn, Kalamazoo, MI, USA) plus 200 g/ml DNAse (Sigma, St Louis, MO, USA) and incubated at room temperature for 20 min. C/T MNC were pelleted by centrifugation at 300 g for 7 min and resuspended in fresh LTBMC medium. Aliquots of thawed cells were assayed to determine nucleated cell concentration and cell viability. Cells were diluted in isotonic-buffered saline (Diluent 2; Stephens Scientific, Riverdale, NJ, USA) and nucleated cells were enumerated on a Coulter ZM cell counter (Coulter Electronics, Hialeah, FL, USA) after erythrocyte lysis with Manual Lyse (Stephens Scientific). Cell viability was determined using propidium iodide (Molecular Probes, Eugene, OR, USA) staining. After 10 min, cells were washed and resuspended in 0.5 ml phosphate-buffered saline (PBS; Gibco BRL) containing 1% bovine serum albumin (BSA; Leptab-7, Intergen, Purchase, NY, USA) for analysis on a FACS Vantage flow cytometer (Becton Dickinson, San Jose, CA, USA).
Two BM aspirates from each normal donor were pooled and the nucleated cell concentration was determined. MNC were separated by density gradient centrifugation (FicollPaque Plus; Pharmacia Biotech, Uppsala, Sweden; s.g.1.077) at 300 g for 20 min at 25°C. Fresh BM MNC were washed twice with LTBMC medium prior to culture.
Small scale cell culture expansion system
Fresh and C/T MNC expansion cultures were initiated in 24-well tissue culture plates (Costar, Cambridge, MA, USA) at a viable nucleated cell density of 0.5 × 10 6 cells per well in a final volume of 0.6 ml. Ex vivo expansion cultures were performed using LTBMC medium supplemented with recombinant human (rh) erythropoietin (Epoetin Alfa; Amgen, Thousand Oaks, CA, USA) at 0.1 U/ml, rh PIXY321 (Immunex Corporation, Seattle, WA, USA) at 5 ng/ml, and rh flt-3 ligand at 25 ng/ml (Immunex Corporation). Ex vivo expansion cultures were incubated at 37°C in a humidified atmosphere with 5% CO 2 and fed with a 50% medium exchange on days 4, 7, 9, 10 and 11. To prevent cell loss during feeding, medium removed from each well was centrifuged at 300 g for 5 min. The resulting cell pellet was resuspended in fresh expansion medium and returned to culture. Expansion cultures were harvested on day 12 using trypsin/EDTA (Gibco BRL) and Dulbecco's PBS (Gibco BRL). The expanded cell product was enumerated on a cell counter as described above.
Hematopoietic cell assays
CFU-GM: Cells were inoculated in methylcellulose (final concentration 1.0%; Sigma) prepared with IMDM supplemented with 2 mm glutamine (Gibco BRL), 30% FBS, 1.0% BSA, 1% monothioglycerol (Sigma), 0.1% penicillinstreptomycin (Gibco BRL), 5 ng/ml rh PIXY321, 5 ng/ml rh G-CSF (Amgen) and 10 U/ml rh erythropoietin. Triplicate 1 ml aliquots containing 1.0-2.0 × 10 4 cells per ml (fresh and C/T MNC expansion culture inoculums) or 3.0-6.0 × 10 3 cells per ml (expanded cell products) were plated in gridded 35-mm dishes (Nunc, Naperville, IL, USA) and incubated at 37°C in a humidified atmosphere with 5% CO 2 . At day 14 of culture, CFU-GM (colony forming units granulocyte/macrophage) were enumerated as previously described. Cultures were maintained at 33°C in a humidified atmosphere with 5% CO 2 , and fed at weekly intervals with a 50% medium exchange (100 l). After 5 weeks, the wells were harvested using trypsin/EDTA and plated in non-tissue culture-treated 24-well plates (Falcon, Lincoln Park, NJ, USA) containing 0.25 ml methylcellulose medium supplemented as described above. Wells were scored for the presence or absence of secondary colony-forming cells (CFC) on day 14. The absolute number of LTC-IC was calculated based on the maximum likelihood method. 25, 26 Immunocytochemical staining
Quantitation of the tumor cell population present in the C/T MNC samples pre-and post-expansion was determined by ICC staining, as previously described. 27 Ten coded slide preparations containing 5.0 × 10 5 nucleated cells per slide were prepared for each sample. The slides were air dried and stored for up to 1 month prior to staining. Tumor cell antigens were identified using a murine monoclonal antibody cocktail containing 260F9, 317G5 and 520C9, antibodies previously shown to have reactivity against breast cancer cells, with no reactivity against BM cells. 
Statistical analysis
Results of experimental points obtained from multiple experiments were reported as means Ϯ s.d. Significance levels were determined by two sided Student's t-test analysis.
Results
Ex vivo expansion potential of tumor cell positive bone marrow
Inoculum samples for ex vivo expansion were obtained from unpurged C/T MNC harvests collected from stage IV breast cancer patients. After 12 days of ex vivo culture, the total nucleated cell fold expansion averaged 6.67 Ϯ 1.98 (range 3.14-9.13, n = 7 patient samples in triplicate) with a corresponding mean nucleated cell yield of , n = 7 patient samples in triplicate). Due to variability in the CFU-GM content of the C/T MNC inocula, the corresponding CFU-GM-fold expansion averaged 11.37 Ϯ 3.76 (range 5.68-16.75, n = 7 patient samples in triplicate). LTC-IC, as determined by limiting dilution analysis, were maintained or expanded in six of seven tumor cell positive C/T MNC samples.
Ex vivo expansion potential of tumor cell positive C/T MNC harvested from stage IV breast cancer patients was not significantly different from that of fresh BM MNC obtained from normal donors. As shown in Table 1 , nucleated cell expansion potential, expanded nucleated cell yield, CFU-GM expansion potential, expanded CFU-GM yield, LTC-IC expansion potential, and expanded LTC-IC yield for tumor cell positive C/T MNC obtained from BM harvests were not significantly different from the respective values obtained from the ex vivo expansion of fresh MNC collected from normal donors by small volume BM aspiration.
Reduction in tumor cell content during ex vivo expansion
The effect of ex vivo expansion on tumor cell content was evaluated using ICC staining. Immunostained cells were considered positive for tumor cell identification when staining was observed on at least 75% of the cell membrane and cytoplasm, and the cell morphology was consistent with an epithelial tumor cell. This technique can detect one tumor cell in 10 6 normal BM cells. 6 nucleated cells, respectively. Viability testing using propidium iodide indicated that more than 92% of cells were viable after ex vivo expansion. As shown in Table 2 , the amount of tumor cell contamination in the culture inocula did not correlate with the subsequent ex vivo expansion potential. The total numbers of tumor cells remaining in the expanded cell products were significantly less than the initial numbers present in the preexpansion culture inocula. A tumor cell reduction of 1 to 4 logs occurred during the ex vivo expansion process.
Discussion
In contrast to the therapeutic use of BM harvests or apheresis of PBPC, ex vivo expansion of small volume BM aspir- ates may provide a hematopoietic cell product with reduced levels of tumor cell contamination. Previous studies from several groups have documented the safety of an ex vivo expanded BM or PBPC stem cell product for transplant. [29] [30] [31] [32] We recently demonstrated the ability to expand small volume BM MNC separated from WBM aspirates (р40 ml) using a stromal-based perfusion culture to obtain sufficient cells for successful hematopoietic engraftment following myeloablative chemotherapy in advanced stage breast cancer patients. 33 While sustained clinical engraftment requires long-term follow-up, we are encouraged by these findings. All patients enrolled in our clinical studies had histologically normal BM biopsies. An earlier report of successful hematopoietic engraftment using an ex vivo expanded cell product derived from PBPC did not include a myeloablative chemotherapy regimen. 29 A more recent report by Holyoake et al 30 indicated that unlike ex vivo expansion of BM MNC in a stromal-based perfusion culture system, the ex vivo expansion of CD34 + PBPC in gas permeable bags did not provide a hematopoietic cell product capable of providing short-or long-term engraftment following a myeloablative chemoradiotherapy regimen.
This study confirms our ability to successfully expand BM MNC harvested from tumor cell positive stage IV breast cancer patients, with total and progenitor cell expansions equivalent to normal BM. Expansion of BM MNC from tumor cell positive stage IV breast cancer patients in the small scale culture system was similar to expansion of BM MNC from tumor cell negative advanced stage breast cancer patients in the Aastrom Cell Production System using the same cytokine conditions as listed in Materials and methods. Mean total cell fold and CFU-GM expansions in the small scale vs the clinical scale system were 6.7 vs 6.4 and 11.37 vs 12.2, respectively. 33 LTC-IC were maintaned during ex vivo expansion in both the small scale and clinical scale systems. Although the number of LTC-IC does not equate with the presence of long-term repopulating cells, 30, 34 infusion of our expanded cell product provided sustained engraftment following a myeloablative chemotherapy regimen. This suggests that our ex vivo expanded cell product derived from BM MNC contains the necessary cell population(s) in sufficient number(s) for the reconstitution of hematopoiesis. Sustained long-term engraftment with our expanded cell product can only be confirmed as these patients are followed over time.
In addition to successful expansion of hematopoietic cells, passive purging during ex vivo expansion in a small scale culture system decreased the tumor cell frequency and the total tumor cell content contained in the resulting cell product. The sensitivity of ICC staining can be increased by evaluating a higher number of cells. Our evaluation of 5 × 10 6 nucleated cells exceeded the 95% confidence limit of sensitivity for ICC staining, which is about one tumor cell in 10 6 nucleated cells for 3 × 10 6 cells examined. 35 Alternate methods of epithelial tumor cell detection, such as the more sensitive reverse transcriptase polymerase chain reaction based on cytokeratin 19 and clonogenic assays are required to verify the reduction in tumor cell content. The patient MNC samples analyzed in this study were aliquots of processed BM harvests obtained by bilateral aspiration from two to four skin sites per side, with 10 to 20 bone punctures per skin site. We expect the initial tumor cell number contained in a small volume BM aspirate to be less than the amount present in the BM harvests reported here. It is likely that reductions in the total volume of BM collected (0.5-1.0 l/BM harvest vs 0.04 l/small volume BM aspirate) and the number of bone sites sampled (bilateral/20-80 sites vs unilateral/two sites) would contribute to lower tumor cell number in the small volume BM inoculum, which may further reduce the tumor cell content in the expanded cell product.
Initially, apheresis products were considered to have less tumor cell contamination than BM harvests. 17 Subsequent studies indicate that tumor cell contamination in mobilized PBPC collections remains frequent, 23, 36, 37 indicating that apheresis is not a reliable method for eliminating tumor cells from the hematopoietic cell product. Due to the infusion of greater numbers of hematopoietic cells in PBPC collections, the actual numbers of tumor cells reinfused may be similar to that in BM harvests. Apheresis of breast cancer patients may be further complicated by the less uniform, thus less predictable, mobilization pattern in patients who have previously received myelotoxic chemotherapy. In addition, tumor cell contamination of PBPC can occur regardless of the patient's clinical status at the time of apheresis. 38 Mobilization for PBPC collection also has the potential of mobilizing tumor cells from sites other than the BM, or from areas of BM metastases not sampled in a small volume aspiration or harvest. These negative factors associated with the collection of mobilized PBPC in breast cancer patients would be eliminated with the infusion of a cell product obtained by ex vivo expansion of MNC from a small volume BM aspirate.
Although active tumor cell purging using chemical agents or antibodies can be employed to decrease the number of tumor cells reinfused with the hematopoietic cell product, these procedures have many disadvantages including toxicity to normal cells, stem cell loss, and uncertain efficacy. Positive CD34 + cell selection of BM harvests or PBPC collections from breast cancer patients has been shown to reduce the number of detectable tumor cells in the hematopoietic graft. 39 As in the study by Shpall et al, 39 tumor cell content after ex vivo expansion was reduced in all samples examined, but remained above detectable limits in some of the samples. Additional ex vivo expansion studies using MNC from small volume BM aspirates, rather than aliquots of BM harvests, are required to determine if the reinfused tumor cell content can be reduced below detectable limits in a higher percentage of cases. Passive purging in our ex vivo culture system offers a simpler method of tumor cell reduction, as the large number of cells provided by multiple PBPC collections or BM harvests make purging and positive CD34 + cell selection costly and difficult to perform.
In vitro clonogenic assays suggest that tumor cells remaining in BM harvests or PBPC collections can be viable and clonogenic. 12, 13, 17, 18 The clonogenic potential of residual tumor cells detected after ex vivo expansion in our culture system has not been determined. Although the contribution of reinfused tumor cells to disease relapse remains controversial, several recent studies suggest that reduction in the number of tumor cells reinfused may delay and potentially reduce the frequency of disease relapse in breast cancer patients. 6, 9 These studies employed immunologic techniques which increase the sensitivity of tumor cell detection. Analysis of 246 patients indicate a decreased overall survival in stage IV breast cancer patients who received a transplant with BM or PBPC containing detectable contaminating tumor cells. 9 Additional studies suggest BM metastasis and higher numbers of tumor cells identified in the reinfused cell product correlate with decreased disease-free and overall patient survival in patients with multinode positive breast cancer treated with chemotherapy. 6 The data reported in this study demonstrate that ex vivo expansion of tumor cell positive C/T BM MNC from stage IV breast cancer patients will yield total and progenitor cell numbers equivalent to that of normal expanded BM MNC with concomitant reduction in tumor cell content by passive purging during the culture period. We expect the use of MNC from a small volume BM aspirate as inoculum for ex vivo expansion would further decrease the level of tumor cell contamination in the reinfused cell product, as compared to the use of a full BM harvest or apheresis products for stem cell transplantation. Reduction in initial BM sample volume, reduction in the number of BM aspiration sites required for sample collection, and passive purging during ex vivo expansion could result in a potential 2 to 4+ log reduction in tumor cell content in the reinfused cell product. Further studies evaluating the clonogenic potential of tumor cells will be performed to accurately reflect the viable tumor cell content remaining in the ex vivo expanded cell product. Clinical trials using the Aastrom Cell Production System are underway to determine the therapeutic benefits of the expanded cell product in breast cancer patients and further investigate passive tumor cell purging during ex vivo expansion. Long-term patient follow-up will aid in determining the contribution of reinfused tumor cells to disease relapse in breast cancer patients and the ability of an ex vivo expanded cell product to provide sustained engraftment. Gene marking studies may also elucidate the significance of contaminating tumor cells.
